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CHAPTERl
INTRODUCTION
ImmuDobiology of the Skin
Skin 1S a highly organized dynamic system where cells constantly divide.
selectively migrate. differentiate and die. All these activities make skin a sturdy
physiological barrier to harsh environments. Although the skin acts primarily as a dry
mechanical barrier by constantly ridding itself of contaminating or,ganisms by means of
desquamation, it also adapts itself to various roles with great versatility. It aids in thermo-
regulation, acts as a sense organ, is a source of endocrine mediators, and initiates and
sustains various immune responses.
Until the late 1960s, skin was not recognized as an organ capable of immune
responses. In the 1970s, Streilein noted that skin has afferent and effer nt lymphatics.
lymphocytes, WBCs and dendritic cells and is hence capable of immune functions (114).
Later Margaret Kripke and her coworkers showed for the first time that UV light causes
tumors in the skin of mice by local immunosuppression (l05). Fichtelius described skin
as a primary-lymphoid organ in 1970 (63a), but his concept remains unproved. Though
no specific evidence exists for categorizing skin as either a primary or a secondary
lymphoid organ, its involvement in the generation and the regulation of immune reactions
has led to the coinage of various terms to describe a relationship between skin and
immunology. The foremost term that was used in the literature to refer to this relationship
was Skin Associated Lymphoid Tissue (SALT) introduced by Streilein and his co-
workers in 1978 (202). In 1986, Bos and others proposed the term Skin Immune System
(SIS) to emphasize the role of skin in immunology (25). In 1989 Sontheimer us d th
term Dermal Microvascular Unit (DMU) to focus on the center of immunological acti ity
(25). Nickoloff in 1993, proposed Dermallmmune System (DIS), a concept that r lat s to
the cellular and humoral aspects of SALT (25). Whatever the term used, tbe main point
is that skin actively participates in immune surveillance. The concept of SALT
encompasses or accounts for the presence of cells capable of ingesting, processing and
presenting antigens, the presence of specific peripheral lymph nodes for reception of
immune-related stimuli, the existence of T cells capable of directional movement and
production of immuno-regulatory molecules such as cytokines and chemokines (202).
The constituents of SALT are keratinocytes (KC), langerhans cells (LC), epidermal T
cells, vascular endothelial cells, lymphatic endothelial cells and draining lymph nodes. To
describe the complexity of immune response assooiated cells, SIS system is more valid.
The cellular components of SIS are LC, KC, macrophages, granulocytes, mast cells,
endothelial cells and T cells while their humoral components are anti-microbial peptides,
complement proteins, immunoglobulins, cytokines, coagulants, prostaglandins and free
radicals (24). Thus, it includes both the innate and adaptive parts of immunity.
Some of the facilitators of a successful immune response in skin include antigen
presenting cells (APCs), accessory cells, immunocompetent lymphocytes and soluble
mediators. KCs comprise the major portlon of the all epidermal cells (approximately 90
to 95%) and possess the abilIty to elaborate a number of cytokines that modulate
immunological reactions (128, 110, 75, 102). Cytokine production by KCs reflect on their
possible role as accessory cells as well as the fact that KCs can be induced to express la
antigens, intercellular adhesion molecule 1 (rCAM-1) and other surface molecules under
certain diseased conditions such as graft versus host disease (GVHD), allergic contact
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dermatitis, lichen planus and inflammatory dermatoses (1'0) or in response to certain pro~
inflammatory cytokines (54). In short, KGs have all the relevant signals needed for
accessory cell function but whether they function as accessory cells remains to be seen.
As opposed to KCs, LCs comprise only a minor portion of epidermal cells though th if
role as inducers of immune reactions is indisputable. Les belong to a class of
professional APCs that have a unique trait of inducing primary immune responses (201).
They are strategically located in the epidermis,a region that is continuously exposed to
innumerable antigens, posing as sentinel cells. They pick up antigens, process them and
put them up on the cell surface prior to journeying down to the afferent lymphatics via
endothelial cells. The intermittent cohesion and separation of various adhesion molecules
expressed on both immune-related cells and endothelial cells facilitate transendothelial
cell trafficking. Endothelial cells not only aid in LC migration but also in lymphocyte
homing to skin and other organs (154). The oocurrence of the synchronized spatial and
temporal events necessitates interaction with endothelial cells in a very compI x mann r.
In addition to these cells participating in cutaneous immunity there are dendritic
epidermal T cells in murine epidermis that may playa role in induction of tolerance and
immune surveillance (226), and dermal dendritic cells, mast cells and macrophages,
which may provide an interface with the external environment. All these cells and the
interactions among them, by the way of soluble mediators and surface molecules, give
the complete picture of immunophysiology of skin.
Layers of the SkiD
Skin is one of the largest, one of the most structurally diverse and the most visible
organ of the body. It is in direct contact with the external environment, which governs its
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functions and detennines its structure. It can be defmed as a multifunctional system that
sheaths and protects the body both passively as well actively. Skin or integum nt can
conveniently be classified into four zones, the ectoderm-derived epidermis tb
mesoderm-derived dennis, separated from each other by a junction, basement membrane
and subcutaneous fatty tissue. It also includes glands and its various modifications. The
outermost layer of the skin that is always in a state of constant renewal is epidermis. It is
multi-layered tissue, externally composed of cornified squamosal epithelium. The five
distinct layers of epidermis working downwards are stratum corneum, stratum lucidum,
stratum granulosum, stratum spinosum and stratum basale, also known as stratum
germinativum. Stratum corneum is usually composed of flattened, squamous, hexagonal
keratinized dead cells arranged in peculiar columns (37). Cell proliferation and
replacement are hormonally regulated (232). It essentially prevents desiccation,
modulates temperature changes and protects from exogenous agents. The next layer,
stratum lucidum, has compactly packed cells with degenerate nuclei and indistinct cell
borders. By the time the cells reach up from germinal layer, they lose their full set of
essential organelles. Stratum granulosum consists of four to five layers of polygonal cells
with rounded nuclei and endoplasmic keratohyalin inclusions, which were speculated to
be precursors of keratin. The layer below the granular layer is the stratum spinosum with
its polyhedral shaped cells. These cells when separated exhibit "spiny" morphology hence
the name. The cells in this layer are in contact with each other via intercellular bridges,
desmosomes and tonofibrils. They show active division but less frequently than the cells
in the layer beneath it, the basal layer. The keratinocytes as they pass this layer undergo a
process called keratinization.
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Stratum basale is the chief cell-producing layer of the epidennis. The cells in his
layer appropriately have more mitochondria and high enzymatic activity. The high lev I
of growth and division is supported by an easy access to nutrients from neighboring
dermal blood vessels. The cells are columnar or cuboidal in shape with their one surface
resting on the basement membrane. Keratinocytes grow from basale and acquire
connective junctions as they move up, which helps them keep anchored to each oth r.
LCs reside in the basal and the supra-basal region attached to the neighbouring Kes via
E-cadherin and Ca++ dependent mechanisms.
The dermis is directly present beneath the epidermis and is separated from it by a
non-cellular basement membrane, which serves to prevent the movement of materials and
cells across the junction (200). Dermis consists of connective tissue, collagen, reticulin,
elastin fibers, fibrocytes, tissue macrophages, mast cells, nerves, lymphatics and blood
vessels. Dermis has two indistinct layers: stratum papillaris, the papillary layer and
stratum reticularis, the reticular layer. The former layer is far richer in cells, blood
vessels, nerves and extra-vascular leukocytes than the latter. In most inflammatory
conditions, the responses are always greater in papillary layer than in reticular layer. The
dermal layer is essential for the viability of epidermis, thermo-regulation and cell
infiltration in skin immunity.
Langerhans Cells: Ontogeny, Morphology and Function
Paul Langerhans, in 1868, described a peculiar looking cell in humans having
dendritic processes in the suprabasal region of epidermis on gold impregnation. He and
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the other researchers believed that these cells should be classified as a part of the n rvous
system (112). In 1926, Masson suggested that LCs were precl.U"sors ofmelanocytes (133).
Only during the past three decades, the concept that LCs may have immune-related
function was explored and accepted.
In the early 1960s, Breathnach and others showed that LCs were neither related to
nerve cells nor to melanocytes (26). Only recently Katz demonstrated that LCs originate
from a pool of bone marrow derived mobile progenitor cells (90). This observation was
further reinforced by Frelinger et.a1. when they illustrated synthesis of LCs in X-
irradiated chimeric mice from bone-marrow derived donor cells (65). Precursors of LC
were speculated to be of myeloid origin because they express myeloid surface molecules
like CDll, CD13 and CD33 (69) and were presumed to immigrate to the skin through
blood circulation. Transforming growth factor pI (TGF 131) (22) has been demonstrated
to be an essential requirement for in vitro development of CD1a+, E-cadherin+ and BG+
LC from CD34+ stem cells, under serum free conditions, in the presence of granulocyte
macrophage-stimulating factor (GM-CSF), tumor necrosis factor ex (TNFa), (31) and
colony stimulating factor (CSF), while FLT-3 ligand was implicated in enhancing this
development process (209). The complete set of signals needed for in vivo development
and differentiation of LCs, from proliferating stem cell state to a precursor state, and
intermediate stages involved in the development and the functional specialization of LCs,
en route to skin are hardly known. Although a recent study suggested the involvement of
GM-CSF, in the emigration of LC into the skin and in the maturation of LC, ill vivo (29).
LCs exhibit a unique morphology. They have dendritic processes that interdigitate
between keratinocytes and these processes can be seen with an aid of a light microscope.
As mentioned previously, they are located in the basal and the suprabasal region of the
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epidennis and make up 2 - 4% of the epidennal cell population. The most ~ liabJ
marker that can only be visualized under electron microscope (78), in LC is the birbeck
granule (BG). It is a rod shaped intracellular organelle speculated to have formed via an
endocytic process (79) with an unknown function (18). Teunissen et al. have tentatively
associated BG with antigen-trapping and antigen-presenting functions of Les (218). The
other classical markers used to identify Les are la antigens, which are encoded by MHC
II genes and membrane-bound ATPase (233, 63). These markers are unique to LC in
normal epidermis and therefore are commonly used in immunochemical staining
strategies. In case of skin disorders, KCs can be induced to express Ia antigen (10) or can
acquire ATPase activity. In addition, LCs express CDla in human epidermis (140), ly-5
antigens in mice (119) adhesion molecules, cytokine and Fc receptors for IgG and IgE
(166, 115). The adhesion molecules intercellular adhesion molecule I (ICAM-I) and
leukocyte functional antigen 3 (LFA-3) (217) are weakly expressed on freshly isolated
LCs though ICAM-3 is constitutively expressed (2). However, the mRNA for
costimulatory molecules CD80 and CD86 is present in the cytoplasm of LCs, but it is not
expressed on freshly isolated LCs from human epidermis (70, 210). Once LCs are
cultured they resemble the mobile class of activated LCs found in vivo. Thus, the
culturing of LCs stimulates LCs to undergo maturation and migration processes in vitro.
The sets of changes that occur during this period are loss of BG, COla, FcyRII
expressions (217), upregulation of MHC I; MHC II, ICAM-I, LFA-3 molecules and
synthesis and expression of CD80 and C086 (217, 216, 210, 165, 70). In brief, the
phenotype or the morphology of LCs depends heavily on its milieu. Les have a vast
number of mitochondria indicating their high metabolic activity, well-developed
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endoplasmic reticulum, golgi bodies and lysosomes (231). Their phagocytic capacity was
found to be considerably less than that ofmacrophages and KCs (231).
The principal physiological functions of LCs in skin appear to be antigen
recognition, antigen-uptake, antigen processing and seleotive migration towards T cell
rich areas in order to present antigens to naIve T cells (203, 204,179). While perforrning
all these functions LCs differentiate from an immature state to a mature state that finally
culminates in a apoptotic death (134). LCs have also been implicated in contact
hypersensitivity, skin-graft rejection, allergy and cutaneous immunologic tolerance.
Antigen presentation:
LCs similar to other DC's express pattern recognition receptors, complement
receptors and Fc receptors that are involved in recognition and uptake of antigens.
Studies suggest that LC express a mannose receptor that probably acts as an antigen
receptor (161) and IgG receptors: CD32, CD64 and both high and low affinity receptors
for IgE (164) that allow for specific uptake of opsonized antigens. Once the antigen is
engulfed via macro-pinocytosis or receptor mediated endocytosis (l 71), the next stage
involves antigen processing. LCs belong to a professional class of antigen presenting
cells that present exogenous antigen in conjunction with MHC class II molecules to CD4+
T-cells (29). The MHC II molecule is synthesized and translocated to ER where it is
associated with invariant chain. This complex is then moved to the endosomal
compartment of the Golgi. The engulfed antigen is processed to a peptide form, which
then binds with the cleaved MHC molecule in the MHC II compartment (MIIC), and is
subsequently transported to the cell surface (145). This is a very important event because
neither MHC II nor antigen individually can activate unprimed T cells due to the high
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specificity of T cell receptor (TCR) for antigen. Lanzavecchia and oth rs noted that
efficiency of antigen uptake is crucial for peptide loading and presentation by MHCclass
n (113). In the nonnal unperturbed tissue, LCs have a strong antigen capture capacity but
low APC activity hence they are termed as immature. Upon activation, LCs undergo a
process of differentiation that triggers changes in the level of expression and repertoire of
cell surface molecules. During in vitro cultivation of LCs for 2-3 days, differentiation
signals are obtained from their microenvironments that in tum induce the maturation of
LCs into potent immunostimulatory cells. These signals can be in the fonn of cytokines
such as GM-CSF, ll..,-lP, ll..,-la and TNFa (81). Once LCs are activated, they acquire a
high level expression of MHC n, ICAM-I, ICAM-3, LFA-3, C080, CD86, C040 and
ability to produce ll..,-1, ll..,-6, IL-12 and ll..,-15 (70, 216, 217, 198). Some of them serve
to trigger migration of LC from the cutaneous region to peripheral lymph nodes and some
to initiate T cell responses. In particular, TNFa and ll..,-1 p have been demonstrated to
cause LC migration (41, 43) as well as downregulation of E-cadherin that cements LCs to
the neighboring KCs (183). Besides these, two other molecules implicated in LC
migration are CD44 and integrin chains a6/b 1 (156, 225). On reaching the lymph node,
the antigen-MHC n complex on LC physically interacts with the TCR-C03 complex on
T-cells essentially delivering one signal while the binding of CD80/CD86 with their
ligand CD28 on T-cells delivers a second signal for activation (180). Induction of a
cascade of cytokines by activated T-cells, followed by upregulation of homing receptors
on T-cells paves the way for their recruitment into skin (155) and a full-blown cell-
mediat~j response.
Contact hypersensitivity:
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LCs play a dominant role in the induction of T-cell activation in respons to
contact sensitizers.. The proof that LCs serve as target structures in contact
hypersensitivity type IV (CHS IV) reactions in humans on exposure to DNCB was
gathered by Silberberg in 1976 (188). Since then other investigators have shown
induction of delayed hypersensitivity reactions on exposure to haptens in a high LC
density area whereas in a LC deficient area the same hapten application induced
unresponsiveness or peripheral tolerance (219). Haptens are small chemical molecules
that bind to a protein carrier, which confers immunogenicity. When the haptens are
painted on the skin of sensitized individuals, the LCs gradually disappear from the
epidermis, migrate to the draining lymph node, activate CD4+ T cells, which then
selectively migrate to skin, causing a local intracutaneous inflammation characterized by
the presence of erythema and swelling (103, 106, 189, 217) as seen in the case of contact
dennatitis. Although the mechanism of triggering and controlling the migration of LC is
unclear, some recent studies indicate that caspase1 may playa role (7). It has also been
speculated that certain cytokines like TNFa., IL-1P (59), secreted by KCs following
hapten painting provide signals for LC migration. Adhesion molecules such as ICAM-I
are believed to playa central role since anti-ICAM-l moAb blocked the APC function of
EC in a hapten-painted mice (142).
Allergy:
Allergens may cause inflammation vIa triggering accumulation of
immuno~ompetent cells in dermis and epidennis, glvmg nse to specific clinical
•
manifestations such as atopic dennatitis. Studies indicated the presence of the high
affinity receptor for IgE (Fcc:RI) on LCs in patients with atopic dennatitis (27). LCs with
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these receptors apparently present the airborne allergens such as mites and pollen to
specific Th2 subtype-cells which in turn may trigger a cascade of events resulting th
activation of mast cells and basophils (28, 224). It was recently shown that ll..r4 plays a
key role in upregulation ofFceRl on human ODla+ Les in atopic dermatitis patients (67).
It has also been suggested that protein kinase C~ (PKC) may provide a signal for LC
mobilization in allergic and in irritant contact dermatitis cases (163).
Skin graft rejections:
In the murine system it was demonstrated that LCs induce allogeneic epidennal-
cell-lymphocyte reaction indicating their involvement in allograft rejection and the graft-
versus-host reaction (1) and it was also demonstrated that murine grafts depleted of LCs
survived longer on I-region-disparate hosts (206). A study by Larsen et. al. suggests that
epidermal LCs migrate from skin to afferent lymphatics and initiate transplantation
rejection (117). The upregulation 0 f cytokine IL-IO and lowered expression of MHC II
molecules have been held responsible for the tolerogenecity of neonatal skin grafts (48).
In organ systems like the pancreas, eIiminati.on of Ia+ de~dritic cells (DCs) facilitated
acceptance of pancreatic grafts in rats (61). In addition to decreased MHC II expression,
decreased B7 costimulatory molecule expression in photodyanamic-treated mice led to
prolonged graft survival (147).
Immunological tolerance:
Les playa decisive role in inducing immune responses as well as establishing
tolerance. The knowledge concerning either immunogenic properties of LC or the factors
that transform LC to be tolerogenic can be exploited to design vaccines against
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neoplasms and micro-organisms, to control allergies, to treat skin djsorder'S and to
prolong graft survival. One of the extraneous factors responsible for hyporesponsiven ss
is UVB radiation. Dandie et al. observed in mice that even after two weeks aft r
exposure, LCs were not capable of functioning oonnally (45). UVB irradiation has been
shown to deplete the epidennal LC population (16). When these areas were exposed to
contact sensitizers, CHS was not induced (219). This led to the belief that the ability of
the skin to support the induction of CHS or specific unresponsiveness was influenced by
the presence of functionally intact LCs (207). It was shown that suppressor T cells were
responsible for induction of tolerance in vivo (226). Cytokines IL-lO (58), TGF-p (208)
neuropeptides (98), a-melanocyte stimulating honnone (126), lowered B7 expreSSIon
(101) have been implicated in establishing DC tolerance and T cell anergy.
Epidermal Cytokines and Chemokines
The emigration of LCs from skin to dermal lymph nodes is essential to mount a
cell-mediated response and hence immune surveillance. Prior to migration, LCs have to
become functional antigen presenting cells. This activation and the imminent migration
of LCs are initiated and regulated in part by KCs derived inflammatory mediators called
cytokines. Cytokines arc low molecular weight proteins that are produced in a tightly
controlled manner, by various cell types and act in both paracrine and autocrine fashion
(8) as soluble mediators of immunity, inflammation, cell growth and differentiation in
either synergistic or antagonistic way (127). The first cytokine discovered in 1976,
interleukin 2 (IL-2), promoted in vitro T cell growth (139). Later it was discovered that
12
cytokines represent a wide array of different molecules with overlapping biological
activities: hence, their function is considered as pleiotropic and redundant. Th se
features emphasize the importance ofcytolcines in cellular function. Cytokines can
induce expression of other cytokines (52, 91), interact with other mediators such as
hormones, and bring about a cascade of events. Epidermis has been termed as a "cytokine
factory", having producer and responder cells as well as the cytokines themselves
responsible for skin disorders including contact allergy, atopic eczema, psoriasis etc. (56,
213). Some of the constitutive and inducible epidermal cytokines are IL-la., IL-lP, IL-6.
IL-I0, IL-12, GM-CSF, TNFa. and interferon y (IFNy). The cytokines IL-la., TNFa. and
GM-CSF will be dealt in detail below.
Chemokines belong to a family of cytokines with cell-specific chemotactic activity.
The three sub families of chemokines,. a.-chemokines or C-X-C chemokines, P-
chemokines or C-C chemokines and y-chemokines or C-chemokines are differentiated
based on their protein sequence and function. The members of a.-chemokine are
chemotactic to basophils, lymphocytes and keratinocytes and are mostly produced by
KCs in the epidermis (21). The members of ~-chemokines subfamily, MIP-1 a, MCP-l,
MCP-3, RANTES and MDC are chemotactic for macrophages/ monocytes, T cells and
DCs (12, 71, 193, 235). MCP-3 and RANTES are produced by KCs on challenge with
allergen (237) and are potent attractants for eosinophils; T cells macrophages and APCs
(178, 193). MIP-3a. has been shown to playa role in LC precursor recruitment into the
epithelium during inflammation (49) while MCP-l does the same in the absence of
inflammation too (141). The stimuli for regulation of chemokine expression are provided
by cytokines such as IL-l P and TNFa. (72) as well as contact sensitizers tolerogens and
irritants (138).
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IL-l:
The a-l triad that includes IL-I a., IL-IP and IL-I RA (receptor antagonist) are 17-
20 kDa proteins mainly involved in the initiation and maintenance of inflammation.
Originally named as epidermal cell thymocyte activating factor (ETAF), IL-l was the
first cytokine detected in epidermal cells (128). ll.r1 transcription in monocytes was
induced by adhesion to surfaces, lipopolysaccaride (LPS), S. aureus, IL-l itself, phorbol
esters, zymosan, TNFa., IFNy, Calcium ionophores, C5a, indomethacin and GM-CSF
(46, 62, 82). IL-l a. and IL-lp show similar biological activities since they bind signal
transducing type I receptor with similar affinity (53). Some of the responder cells in
which IL-l induces proliferation are fibroblasts, smooth muscle cells (158).
keratinocytes, hematopoetic precursors, Th2 cells and mature B cells (50). The other
biological implications of IL-I include induction of other cytokines expression such as
IL-6. TNFa, GM-CSF from KCs; induction of TNFa. and adhesion molecules on
endothelial cells; induction of acute phase protein in hepatocytes; differentiation and
surface IgM expression on pre-B cells; and immunoglobulin secretion from mature B
cells; IL-2R expression and chemotaxis of T cells; and augmentation of macrophage
cytotoxic activity. IL-l plays physiological roles that influence pathological conditions
such as fever, cachexia, wasting, septic shock, rheumatoid arthritis and atherosclerosis
(51). Some of these observations are supported by the fact that the inhibitors ofIL-l are
capable of suppressing such responses in vivo (60).
In epidermis, as mentioned earlier, KCs produce constitutively IL-l a., a cytokine
essential for peripheral T cell activation. LCs are induced to produce IL-l P upon skin
sensitization (59). IL-l P is important in the context of LC migration and cytokine
upregulation (57).
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GM-CSF:
GM-CSF IS a 20-30-kDa glycoprotein named after the ability to indue
proliferation and maturation of granulocytes and macrophages. Bacterial ndotoxins,
phorbol esters, TNFa, IL-1a and macrophage activating proteins can induce it. GM-CSF
is a polyfunctional regulator that affects the growth and function of KCs DCs,
endothelial cells, T cells; increases DNA synthesis in transformed cells; enhances
neutrophil chemotaxis; and augments the turnoricidal and the anti-microbicidal activity of
neutrophils and macrophages (167). Excessive levels of GM-CSF can lead to blindness
and muscle wasting in mice (111) and mild flu-like symptoms, rashes, capillary-leak
syndrome and respiratory distress in patients (215).
In the skin, GM-CSF production has been observed both at the mRNA as weLL as at
the protein level in fibroblasts, mast cells, macrophages and endothelial cells and in KCs
it is induced upon reception of stimuli such as antigen, allergen, irritant, IL-l, UV-
irradiation or inflammation (228). It was found to be important for LC viability in vitro
(230). LC generation from precursors, antigen-presenting ability of DCs (86) and LC
migration (168). Because of its potent immune-enhancing properties, is being exploited
as a vaccine adjuvant in flu-vaccine, tumor vaccine, hepatitis B vaccine and HIV vaccine
(211 ).
TNFa:
TNF is a 17-kDa protein originally described as macrophage-derived cytokine and
also is known as cachetin and necrosin because of its biological effects. Macrophages,
NK cells, T cells, B cells, granulocytes, fibroblasts, mast cells, smooth muscle cells,
epidennal cells and tumor cells primarily produce T F. It is produced in response to both
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gram-positive and gram-negative bacteria and their products; UV-radiation' mycoplasma'
immune complexes; cytokines such as GM-CSF, ll..,-IP, ll..,-2, IF y; tumor cells C5a"
PKC activators; protein phosphatase inhibitors; platelet aggregating factor (pAF) among
others. TNF displays a broad spectrum of effects, which includes inhibition of tumor
cells hence its therapeutic application as anti-tumor agent proliferation of fibroblasts
expression of adhesion molecules on endothelial cells, induction of cytokines, induction
of MHC expression on various cells. It exhibits peculiarly contradictory effects such as
viricidal effects against DNA and RNA viruses and induction of viral replication (234,
148). TNFa was demonstrated In vitro, to activate phagocytes to kill bacteria; fungi;
protozoa and helminths (229).
In epidermis, the expression of TNFa by keratinocytes is upregulated by allergens,
LPS and UV-radiation (102). In cutaneous immunity it exerts its influence by increasing
production of IL-Ia by KCs (110), causing migration of LCs from epidermis (31),
infiltration of macrophages, neutrophils and CD4+ T cells in dennis and generating
apoptotic KCs (181). It acts with GM-CSF synergistically to generate LC from CD34+
bone marrow precursors (30).
Costimulatory Molecules: CD80 and CD86
LCs, like other DCs are critical for induction of primary immune responses and
constitutlon of immunological memory (199). Following tissue damage or perturbation of
nonnal skin milieu, Les undergo a learning process, where they transform from a
powerful antigen capturing state to an even more powerful antigen presenting state. One
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of the events that co-ordinates tightly with the maturation process is the upregulation of
costimulatory molecules such as CD40, CD58, CD80 and CD86 on LCs (179)~ Th
maturation of LCs is closely associated with its movement from ep,jdermis to dennal
lymph nodes and eventual priming of quiescent CD4+ T lymphocytes which, is closely
linked with expression of,Ia antigen (186); C080 and CD86 (94, 130, 69, 5); ICAM-l
and LFA-3 (190, 217) on APC. CD80/CD86 expression is predominant over expression
of other costimulatory molecules on mouse dendritic cells (83). CD80 and CD86, integral
membrane proteins, also known as B7-1 and B7-2 molecules respectively (99), are
members of immunoglobulin superfamily that participate in T cell costimulation via
C028 and cytotoxic T lymphocyte antigen 4 (CTLA-4) ligands, surface proteins, on T
cells (176, 179, 230). Witmer-Pack and others have demonstrated that in the absence of
costimulation by C080/C086, TCR engagement is incapable of delivering effective
signal in inducing T cell activation and instead induces anergy (179, 230). This
specifically shows that the TCR-Ag+MHC complex provides one stimulus for T cell
activation while COBOl CD86 crosslinking with CD28 provides the other stimulus (176,
222). This enhances T cell survival by augmenting expression of Bel XL an inhibitor of
apoptosis (20). The engagement of C080/CD86 with CTLA-4 on T-cells leads to the
inhibition of T cell activation, validated by the fact that a CTLA-4 null strain of mice
exhibits severe lympho-proliferative disorder (184) and exposure to CTLA-4-lg renders
DCs tolerogenic (94, 124). Some of the mechanisms that were reported to account for the
action of CTLA-4 include induction of apoptosis (73), cell cycle arrest (175) and
establishment of an effective threshold for activation of T cells (93, 107, 122,223).
CD80 and CD86 are differentially expressed and regulated on Les in response to
cytokines (92). Though the molecules exhibit some functional redundancy, in cases like
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detennining Thl response versus Th2 response, they show distinct effects (64, 108). A
study conducted to demonstrate differential Thlffh2 activation pathway showed that
IFNy and ~10 down regulate Th I clonal expansion by suppressing CD80 expression
(149). CD80 expression is positively regulated by cytokines TNFex., GM-CSF but not
IFNy and IL-10; LPS; CD40L feedback (149, 170); by contact sensitizers (146, 162) on
LCs while CD86 expression is positively regulated by few of the same mediators and also
IL-4, but not TNFa. and IL-IO (135). Recent findings showed that CD80 and CD86
mediate costimulatory functions with different magnitude. Expression of CD80 was
reported to have increased the sensitivity of TCR for low affinity ligands (238).
Transgenic mice expressing CD80 on KCs, a ligand normally absent on these cells,
showed enhanced response to topical antigen, underlying its functional significance
(227). Although recent studies indicate that CD86 is the major player in costimulation
(159, 211). It was implicated in inducing allogeneic T cell responses as well as Ag-
induced T cell proliferation (159). Though the mechanism of action is not clear, it is
hypothesized that functional attributes of CD80/CD86 are due to decreasing the
proximity, and facilitating signaling and lowering the threshold of activation.
Blocking of B7-CD28 interaction represents a powerful immunosuppressive tool to
control allograft rejections by maximizing tolerogenic signals (120).
Adhesion Molecules: ICAM-I and LFA-I
As mentioned previously, adhesion molecules aid in selective leukocyte migration
to specific sites during immune responses by interacting with endothelium and aid in the
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costimulation of resting T cens (131,195,38,45). Three classes of adhesion molecules
are known: the selectins, the integrins and the Ig supergene family (195). Des including
LCs, express a variety of adhesion molecules. Some of them are ICAM-l, ICAM-2
ICAM-3, E-cadherin, E-selectin and V-CAM. These molecules exhibit selective
expression and regulation patterns.
In the epidermis, KCs and LCs show the expressIOn of homophilic adhesion
molecules called E-cadherin that acts like cement maintaining the cellular contact.
between the two cells (214). Loss of E-cadherin was found to be linked with
accumulation of DCs in lymph nodes (22). Allergens and cytokines such as TNFa. and
IL-l P have been to some extent implicated in the downregulation of these molecules
(183). Another molecule that is important in LC migration is ICAM-I (27). ICAM-l is a
95-kDa member of the Ig superfamily, also known as CD54, found on leukocytes,
endothelial cells and DCs among others (143). It interacts with its ligand LFA-I, known
as CD 11 a/CD18, a heterodimer surface molecule expressed on all leukocytes (118, 197)
and particularly endothelial cells in the epidennis. It modulates intercellular adhesions
(118, 196) as well as costimulatory effects (109). Antibodies against both these molecules
have been shown to prolong allograft survival (80, 85, 221), reduce the severity of
autoimmune response (l04), and inhibit contact hypersensitivity (129) by blocking
leukocyte migration (167). ICAM-l was shown to have a non-MHC restricted effect on
tumor cells (143, 144). A synergistic effect was observed between CD80 and ICAM-I, in
delivering a more intense second signal for T cell triggering in artificially constructed
drosophila cells (194). T cells also possess adhesion molecules LFA-2 and ICAM-3 that
.
bind with LFA-3 and LFA-Ion DCs and cause upregulation of costimulatory and other
functional molecules (157).
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Maturation and Migration of Langerhans Cells
The strategic location of LCs on the skin surface makes them ideal for monitoring
invasion by extraneous factors and protecting the integrity of epithelial surfaces from
these factors. They evolved to perfonn the role of antigen presenting cells to dormant T
cells. The sequences of steps involved in the life cycle of LC starting from its recruitment
as APC are: capturing exogenous antigens) processing them to small peptides and
complexing them up with MHC n moieties, exporting this epitopio complex on to the
surface, upregulating expression of various costimulatory molecules, downregulating
expression of other molecules such as E-cadherin, undergoing changes in the cell
morphology: depolarization, appearance of filopods, cytoskeletal rearrangement, binding
to Laminin, regulating access across basement membrane, accumulating in lymphatics,
engaging specific surface structures with their respective ligands on T cells, bringing
about activation of T cells and undergoing apoptosis. All these events form an
inseparable part of a maturation and migration process of LCs and are intricately
governed by the changing cytokine scenario.
In the epidermis, LCs are maintained at a specific density (15, 233) and their tum
over rate is low (121, 205). This implies that LCs are not native residents of epidennis
and have immigrated from other organ/organ systems. This was proved by Katz and
others that LCs predecessors are nomadic bone marrow-derived CD34+ cells (90). In vitro
culture of human cells, CD34+ blood cells generated a subset of cells with CDl a, HLA-
DR, CD86 and birbeck granules, in the presence ofGM-CSF and TNFa (30).
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Recently, common myeloid progenitors (CMP) were isolated (132). On
transplantation in irradiated congenic recipients, these progenitors gav rise to LCs. The
homeostasis of LC is believed to be regulated by cytokines. Though in vi 0 factors ar
not clear, it has been shown that GM-CSF, ll...-I and TNFa maintain Les in viable state
in culture (101).
After they develop from progenitors, LCs populate skin and remain In an
unfledged state. They are induced to mature and migrate by a variety of stimuli including
microbial antigens, inflammatory mediators, tissue damage, UV radiation and other
antigen non-specific signals. In vitro oulture of LCs triggers the maturation process and
increases their immuno-stimulatory ability (230). Once the integrity of the skin is
disturbed, LCs undergo phenotypic and functional changes that imitate changes that
occur in cell cultures. Studies indicate that in skin grafts (118) on treatment with skin
sensitizers (4), on exposure to enterotoxins (35) DCs show marked induction of Ia+
antigens as it does on stimulus with GM-CSF, IL-I, TNFa and CD40 ligation (32.171).
IL-1 Pand TNFa are responsible for switching of LC from the Ag-capturing stage to the
Ag-presenting state (172) as they are responsible for shut down of macropinocytosis.
Keratinocytes produce increased levels of GM-CSF, TNFa and IL-Ia expression in
response to danger signals whereas Les produced increase levels of IL-I P (59).
Cytokines have been implicated in activation, maturation via upregulation of various
surface molecules and migration of LCs both directly and indirectly by regulating cellular
adhesions. Recent publication indicated that Cytosine-guanosine (CpG) motifs present in
the bacteria DNA induce LC migration by modifying expression of E-cadherin and
ICAM-I (13). Reynolds and his co-workers have suggested based on their data that LC
migration in the case of CHS involves the PKC-P signaling pathway (163). TNFa has
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been demonstrated to produce subsequent effects that may possibly influence th
maturation and migration process: reduction in the expression of E-cadberin in situ (183
an increase in the expression of ICAM-l (42, 220), induction of the expr ssion of
gelatinase in macrophages (173), chemotaxis for roLC (236) and upregulation of
expression of CD80 and CD40 (170). IL-I P induces expression of gelatinase, reduces
expression of E-cadherin (183), induces expression of other cytokines such as TNFa., IL-
l a, IL-IO, MIP-2 ('57), induce expression of chemokines (11) and thereby regulates both
maturation and migration process. GM-CSF is another cytokine that modulates
maturation and migration process of LCs by upregulating costimulatory molecule
expression (170). IL-l8 has been shown to induce LC migration by an IL-I dependent
mechanism (39).
The significant aspect of LC migration is that LCs do not need to be fully mature in
a functional sense before they migrate from epidermis. This was demonstrated by Larsen
et al. who showed that LC start migrating even before they acquire all the relevant
maturation markers (117). Studies have indicated that LCs enter lymph nodes just after 4
hours exposure to FITC, reach a maximum after 2 days and gradually decline thereafter
(130). As stated in the previous section, LCs start undergoing maturation in response to
external stimuli, while at the same time acquiring molecules that regulates their
trafficking from the epidermis. The two most important molecules on LCs that are
involved in the exodus are E-cadherin and ICAM-l. Downregulation of E-cadherin and
upregulation of ICAM-l on LCs and upregulation of LFA-Ion endothelial cells aid in
direction r I movement of LCs across the basement membrane. The three steps involved
are: a, detachment of LCs from their neighbors, KCs by downregulating E-cadherin
expressIon; b, Attachment of LCs and Endothelial cells via ICAM-I and LFA-I and
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initiating the rolling movement that resembles molecular 'Velcro"; and c,
transendothelial translocation. The migration of LCs is important because the event is
succeeded by the elicitation of antigenic-specifio T cell responses that could have a range
of implications for cutaneous immunity. The pathological importance of this event is
supported by the fact that a murine retrovirus, Rauscher leukemia virus ensures its
survival by blocking LC migration (66).
The factors that are responsible for LC migration are numerous and intricately
linked together. Any strategy that tries to explain this must consider the complex
interactions between various costimulatory molecules, adhesion molecules, cytokines,
chemokines and cell populations. For instance, Kitayarna et al. showed that ligation of
CD80 with CD28 delivers a signal leading to the secretion of ll..,-l ~ (97). Cumberbatch et
al. showed IL-I ~ as one of the main signals for LC migration (41). Thus it remains to be
seen whether ligating CD80 promotes LC migration. The present study endeavors to
examine the effect of antibody against CD80 and focuses on the role of cytokines in an
anti-CD80 induced response.
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CHAPTER II
MATERIALS AND METHODS
Animals
Young female BALB/c strain mice, 6-to-12 weeks old were obtained from Charles
River (Wilmington, MA). These mice were maintained in the Animal Resources
Laboratory, an approved facility at Oklahoma State University.
Media and Solutions
Phosphate buffered saline (PBS, 0.15M) was used as diluent for solutions of trypsin
(type n from porcine pancreas, Sigma Chemical Company, St. Louis, MO),
deoxyribonuclease I (DNase I, from bovine pancreas, Sigma Chemical Company, St.
Louis, MO), antibodies and cytokines. One liter of 0.15 M PBS contains 1.15 g dibasic
anhydrous sodium phosphate (Na2HP04. Sigma Chemical Company, St. Louis, MO), 0.2
g potassium chloride (KCI, Fisher Scientific, Fairlawn, NJ), 0.2 g monobasic potassium
phosphate (KH2P04, E M Science, Gibbstown, NJ) and 8.0 g sodium chloride (NaC!, J.
T. Baker Chemical Co., Phillipsburg, NJ) in 1000 mL deionized water and adjusted to pH
7.2 using 1 solution of HCI before sterilization at 15 psi for 20 min.
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PBS with Tween 20 (pBS Tween, Sigma Chemical Company, St. Louis. MO) was
used as washing buffer and PBS with 10% Fetal Bovine Serum (FBS, Sigma Chemical
Company, St. Louis, MO) was used as blocking buffer in immunohistochemical staining
of epidermal skin section. In the same experiments, skin sections were floatd on 2 M
sodium bromide (NaBr, Fisher Scientific, Fairlawn, NJ) to separate epidermal and dermal
layers.
Skin sections, epidermal cells suspensions were cultured in and cell washings were
performed in sterile RPMI 1640 media (Sigma Chemical Company, S1. Louis, MO)
supplemented with 10% FBS (Sigma Chemical Company, St. Louis, MO), 100 llg/mL
penicillin (Sigma Chemical Company, St. Louis, MO), 0.1 llg/mL streptomycin (Sigma
Chemical Company, St. Louis, MO), 0.1 mM MEM non-essential amino acids (Sigma
Chemical Company, St. Louis, MO), 2 mM L-glutamine (Sigma Chemical Company, 51.
Louis, MO) and 0.1 mM sodium pyruvate (Sigma Chemical Company, St. Louis, MO).
Antibodies
To stain MHC class II (Ia) cell surface antigen, encoded in the I-A region of H_2d
haplotype, on Langerhans cells, purified mouse anti-mouse-l-Ad monoclonal antibody
(Pharmingen, San Diego, CA) of IgG isotype was used.
Purified monoclonal rat anti-mouse CD80 (B7-1) (Pharmingen, San Diego, CA),
monoclopal rat anti-mouse GM-CSF (Pharmingen, San Diego, CA), monoclonal hamster
anti-mouse ICAM-l/CD54 (Pharmingen, San Diego, CA), monoclonal hamster anti-
mouse lL-l ~ (Genzyrne, Cambridge, MA), monoclonal hamster anti-mouse lL-1 a
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COenzyme, Cambridge, MA), monoclonal rat anti-mouse LFA-lICDlla (pharmin n
San Diego, CA), and monoclonal hamster anti-mouse TNFa (pharmingen, San Diego,
CA) antibodies were subcutaneously administered for neutralization. All antibodies were
of the IgG isotype. PBS was used as negative control for in vitro and in vivo studies.
Cytokines
Recombinant munne granulocyte macrophage colony stimulating factor,
recombinant murine tumor necrosis factor a and recombinant munne interleukin-l p
(Genzyme, Cambridge, MA) were added to epidermal cell suspension before performing
immunoassays for TNFa and GM-CSF.
Preparation of Epidermal Sections
Female Balb/c mIce were injected intraperitoneally with neutralizing antibodies
against CD80, GM-CSF, ICAM-l, IL-la, IL-lP, LFA-l, and TNFa individually and
concomitantly with anti-CD80 antibody. After a lapse of two hours in order to let the
antibodies circulate throughout, the mice were euthanized in a CO2 chamber. Hair from
the dorsal side of the mice were removed initially by shaving and additionally by using
an over-tte-counter depilatory lotion (Nair™). After a thorough wash with sterile distilled
water and 70% ethanol, the dorsal skin was surgically removed, the subcutaneous adipose
tissue was scraped off and then the skin was cut into l-cm2 sections in a sterile laminar
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flow hood. These skin sections were then placed epidermal side up on a stack of three
sterile filter disks soaked with 600 ~L of supplemented RPMI 1640 media in a Falcon T I
24-well tissue culture plate. Following 48 hours of incubation at 37° C in the presence of
5% CO2, the skin sections were floated deonal side down on 2 M sodium bromide for 45
minutes at 37° C to separate the epidennis from the dennis. Epidermis was gently pried
off from the dermis with a scalpel in a petri dish of PBS. The epidermal sections were
then stored in PBS at 40 C for future usage.
Immunocytochemical Staining
Epidermal sheets were fixed for staining in HistoChoice™ tissue fixative (Fisher)
for 20 min at 40 C and subsequently washed thrice with PBS. The sheets were then
incubated for 30 minutes at room temperature in 3% hydrogen peroxide to neutralize
endogenous peroxidase activity. Afterwards they were washed three times with PBS-
Tween 20, further incubated in fresh 3% hydrogen peroxide for an additional 20 minutes
at room temperature. Sections were washed again with PBS-Tween and blocked with
10% FBS in PBS for 30 minutes at room temperature. After a final wash with PBS,
epidermal sections were incubated at 4° C overnight with anti-mouse I_Ad antibody.
After incubation with primary antibody, sections were washed and incubated for 35
minutes first with biotinylated anti-mouse 19G antibody from Vectastain™ elite mouse
IgG ABC kit (Vector Laboratories Inc., Burlingame, CA) and followed with Vectastain
ABC
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Female Balb/c mice
(8- 16 weeks old)
i.p. administration of antibodies
(100 ~L in volume diluted with PBS)
2-3 hours of incubation
Skin Explants (in duplicates) incubated for 48 hours at 37° C in 5%
C02 incubator on RPMI soaked filter disks
Epidennis isolated upon treatment with NaBr and subjected to further
treatment with H20 2 and 10% FBS in PBS followed by overnight
incubation with anti-lad antibodies
Epidermal sections treated with Vector-VIP™ immunoperoxidase staining
reagents; sections mounted on slides to enumerate LC
density per square mm.
l~
~
Cells counted under 40X objective
(10 random fields each from two duplicate epidermal sections)
Figure 1. Flow Chart depicting Immunohistochemical Staining
of Murine Epidermis. Ia+ LCs are counted following treatment
with antibodies specific against C080 molecules, cytokines
and adhesion molecules.
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reagent and finally for 12 minutes with substrate solution from Vector VIP peroxidase kit
(Vector). Each treatment was preceded by a washing step. Finally, the sections were
rinsed with distilled water, mounted on a slide in glycerol and quantified for Langerhans
cells with an aid of a microscope. The frequency of Ia+ Les (measured as cells/mm2) was
obtained by enumerating 10 random fields on two duplicate epidermal sections.
Epidermal CeU Suspensions
Each Balb/c mouse was sacrificed with ether and its hair removed using clippers
and depilatory cream. After washing the mouse, the skin from dorsal and ventral sides,
the ears and the tail were surgically sectioned out. In a sterile Laminar flow hood the
subcutaneous layer was scraped out, the skin was cut into two or more manageable
segments and incubated dermal side down in 0.5% trypsin for 45 minutes at 37° C.
Following incubation, the epidermal layers were obtained by smoothing out skin sections
with their epidermal sides down on a clean and a dry petri dish and jerking them gently to
the side. Immediately the exposed basal layer of the epidermis was covered with 0.05 %
DNase. The basal layer was removed from the tail region by using forceps and DNase
was added as before. The samples were rubbed with a blunt-tip glass rod to bring the
cells into suspension. Three volumes of RPM] 1640 medium were added to the
suspension, aspirated approximately 15 times with a 60 cc syringe (Fisher. Fairlawn, 1)
and filtered through a Falcon 70 Jlrn nylon mesh cell strainer (Becton Dickinson, Lincoln
Park, NJ) into a Sarstedt 50 mL test tube (Sartedt, Princeton, J). The cells were then
precipitated out in a Damon CRU-5000 centrifuge (lEe, Needham Heights, MA) for 8
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minutes at 4° C, washed three times to remove all traces of D ase I resuspend d in 1<:)
mL of media and quantified by adding 10 ~L of cell suspension in trypan blu (Sigma
St. Louis, MO) exclusion to hemacytometer. The suspension was finally adjusted to
obtain a desired cell concentration. .,
Cytokine Assays
To assay for TNFa and GM-SCF commercially available Quantikine™ mouse
TNFa and Quantikine™ mouse GM-CSF kits (R&D Systems, Minneapolis, MN) were
respectively used.
Epidermal cell suspension at a concentration of 1.0 x 106 cells/mL was plated out
1.0 mL/well in a 24-well tissue culture plate (Sigma), in duplicates, and stimulated with
50 JlL of 10 Jlg/rnL anti-CD80 antibody, 0.1 Jlg/mL IL-l, 0.01 Jlg/mL TNFa: and 2
Jlg/mL GM-SCF separately and in combination with the fonner. Additionally 50 ilL of
10 Jlg/mL anti-LFA-I was added to a new well containing I mL of cell suspension. 0.15
M PBS was added to the control group and the plate was incubated at 37° C. Supernatants
from each treatment group were directly analyzed for cytokine production after
appropriate incubation times.
TNFa Immunoassay:
This assay employed a quantitative sandwich enzyme immunoassay principle where
a 96-well microtiter plate was pre-coated with purified polyclonal antibody specific for
mouse TNFa. After 24 hours of incubation, samples from various treatment groups were
added in 50 JlL volumes to the well and incubated for 2 hours at room temperature to
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allow binding of mouse TNFa present in the samples to immobilized antibody. Unbound
material was washed away and horseradish peroxidase conjuga ed anti-mous Ig was
added and the mixture was incubated as before. Following a wash to remove any
unbound antibody-enzyme complexes, a substrate solution was added to the wells. The
enzyme reaction subsequently yielded a blue product, which turned yellow on addition of
stop solution. The optical density of each treatment group was read using an EL800
Universal Microplate Reader (Bio-Tek Instruments Inc., Winooski, VE) set to a
wavelength of 450 run. Standard curve for each set of samples was generated by plotting
the mean absorbance value for each standard on the y-axis against the known values of
concentration on the x-axis. Then the sample values were read off the standard curve in
pg/mL.
GM-CSF hnmunoassay:
This assay employed a quantitative sandwich enzyme immunoassay principle where
a 96-well microtiter plate was precoated with affinity purified polyclonal antibody
specific for mouse GM-CSF. After 48 hours of incubation, samples from various
treatment groups were added in 50 ~L volumes to the wells and incubated for 2 hours at
room temperature to allow binding of mouse GM-CSF present in the samples to
immobilized antibody. Unbound material was washed away and horseradish peroxidase
conjugated anti-mouse antibody was added and the mixture was incubated as before.
Following a wash to remove any unbound antibody-enzyme complexes, a substrate
solution was added to the wells. The enzyme reaction yielded a blue product, which
turned yellow on addition of stop solution. The optical density of each treatment group
was read using an EL800 Universal Microplate Reader (Bio-Tek Instruments Inc.,
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Winooski, VE) set to a wavelength of 450 run. The sample values were then obtained in
pglmL from the standard curve generated by linear regression analysis of standard GM-
CSF concentrations versus absorbance values.
Indirect Immunofluorescence
Each epidermal cell suspensions were adjusted to 2 x 107 cells/rnL and 50 J.LL of this
was aliquoted in a 96-well tissue culture plates. The suspensions were then treated with
10 JlglmL of INFo. and 2 JlglrnL of GM-CSF separately and in combination with each
other and incubated for 48 hours at 37° C. The cells were washed twice in 2% FBS in
PBS, centrifuged for 7 min at 1700 rpm and fixed. Cells were incubated on ice with 10
JlglmL of anti-CD80 antibodies for 43 minutes. Washed and centrifuged, the cell
precipitates were then incubated in ice with anti-rat IgG FITC for 40 minutes. After a
final wash and centrifugation step, the cells were resuspended in 2 drops of 90% glycerol
in PBS and mounted on a slide. The cells positive for C080 were counted using a
fluorescent microscope and their percentage was calculated.
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CHAPTER III
RESULTS
The primary aim of this study was to investigate the role ofCD80 in the induction
of Langerhans cell (LC) migration in a murine system and its dependence upon pro-
inflammatory cytokines. The effect of cytokines GM-CSF, IL-la, IL-lP and TNFa on
LC migration has already been elucidated to a certain extent, but not their impact on anti-
CD80 antibody induced LC depletion. Hence, this project also focuses on the latter aspect
of anti-CD80 induced LC migration. All the data recorded were pooled from three
experiments for each investigation and expressed in terms of the standard error of the
mean (SEM). The Student t-test was perfonned to ascertain the statistical significance of
the results. In addition, Dunnetts t-test was used to estahlish the difference between the
mean of the control group and the means obtained from various treatments.
Effects of Antibody against CD80 on I" Vitro LC depletion
CD80 and CD86 are the chief costimulatory molecules that are differentially
expressed and regulated on Langerhans cells (92). These molecules arc involved in
activation of primary resting T cells by providing one signal for the activation while
crosslinking of MHC II-Ag complex with TCR provides the other signal. Interest in the
role of CD80 in LC migration was sparked by a chance demonstration of depletion in LC
number in epidennis on treatment of a mouse with neutralizing antibody against the
CD80 molecule. Hence a series of experiments were performed to examine the influence
of these antibodies on LC migration from epidermis.
For this purpose epidermis was harvested and stained for IA+ cells VIa
immunoperoxidase staining two hours after intraperitoneal administration of Anti-CD80
antibody. Figure 2 indicates that 50 ~g/mL of anti-CD80 antibody caused a decrease in
the density of LC, determined as the mean number of LC per square millimeter of
epidermis in two representative experiments. In another independent research we tried to
determine the dosage effect of anti-CD80 antibody (100 glmL and 200 glmL) as well the
effect of incubation time (24 hours) on LC depletion (data not shown). We found no
substantial difference either due to the increase of antibody concentration or decrease of
incubation period. The controls were from mice that were not treated with any antibodies
and were observed to be with in 800-1000/mm2 range mostly, consistent with
experiments performed by others (42). A Student t-test was performed to establish a
difference between control and experimental groups and this difference was found to be
statistically insignificant. The results from the Dunnett's test emulated basically the
results of the Student's t-test. Indirect evidence to ascertain if the decrease observed
involved migration of LC in response to antibody against CD80 was obtained when
antibodies administered against both ICAM-l and LFA-l adhesion molecules were
shown to have blocked the depletion as depicted in the Figure 2.
This treatment was chosen to verify LC migration due to the fact that other
investigators have found that successful accumulation of LC in draining lymph nodes
occurs on upregulation of ICAM-l expression (44) and also subcutaneous administration
of antibody to ICAM-I and LFA-l led to a complete inhibition of contact
hypersensitivity (129). The results also indicate that antibody to ICAM -1 produced a
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Figure 2. In vitro blocking of Anti-CD80 induced LC depletion by Anti-lCAMl and
Anti-LFA 1 Antibodies. After 2-4 hours on i.p. administration of antibodies, skin sections
were dissected out and incubated on RPMl soaked filter for 48 hours. Epidermal sheets
were then isolated and prepared for immunoperoxidase staining with anti-MHC class II
antibodies. The density of Langerhans cells was determined by counting 10 random fields
per sheet (2 duplicate sheets per experiment). The results are expressed as mean +/- of the
S.E~ from two independent experiments (i.e., 2 mice per treatment group). Statistically
slg~l1ficant difference in the means of the control group and the other groups treated with
varIous antibodies are indicated by an *.
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more pronounced inhibitory effect when compared to treatment with antibody to LFA-I.
No synergistic effect was established as a result of co-administration of anti-ICAM-l and
anti-LFA-l antibodies. Again, the Student t-test showed no significant differ nee
between the various treatment groups. Nevertheless, these results demonstrate that there
is likelihood that anti-CD80 antibody causes LC migration though quite small in
magnitude and this mechanism is in part, dependent upon upregulation of adhesion
molecules ICAM-l and LFA-l. Another observation of note in this experiment is that
anti-LFA 1 specific antibody which belongs to the same isotype class as anti-CD80
(lgG2a) does not cause depletion in LC frequency. This is important because in this study
no IgG controls were used to rule out the involvement of Fc receptors.
Effects of inbibiting LC depletion by Anti-CD80 Antibodies
using Anti-GM-CSF, Anti-IL-la, Anti-IL-IJ3 and Anti-TNFa Antibodies
As previously mentioned, studies have been performed to explain the role of
cytokines in regulating LC migration in response to haptens. Evidence gather d from
these studies indicates that TNFa and IL-l pplaya significant part in mobilizing LC from
epidermis to dermallyrnph nodes (41) while GM-CSF and IL-lo: were implicated in the
process also (168, 185). Therefore our investigations focussed on these cytokines to
determine if they were the candidate cytokines that regulated the anti-CD80 induced
effect on LC migration. The antibodies to these cytokines were injected in combination
with ant'-CD80 in Balb/c mice intraperitoneally. The skins were harvested and incubated
for 48 hours at 37% in a 5% CO2 incubator. The epidermis was then isolated and stained
for I_Ad surface antigen by the peroxidase Vector VIP reaction mixture.
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The results indicated that simultaneous injection of 100 /-11 of 100 /-1g1mL anti-TNFa
antibody blocked the anti-CD80 induced LC dep,letion as assessed by the frequency of
1a+ cells (Figure 3). The anti-CD80 induced effect was statistically significant at the 95%
confidence level as established by both Student's t-test and Dunnett's t-test. Also of
interest in this experiment was the observation that a -27% inhibition of anti-CD80-
induced decrease was achieved with anti-TNF antibody. In Figure 4, it can be noted that
100 ilL of 100 Ilg/mL of neutralizing antibody against IL-l p partially blocked anti-CD80
induced depletion effect. The relatively less significant effect of anti-IL-l p can be
explained based on the indirect nature of 1L-l p'S effect on LC migration suggested by the
work of others (41). The current theory is that IL-IP interacts with keratinocytes to
trigger production of TNFa. But another possibility is that the culture media might have
been contaminated with LPS, a factor with known effect on LC depletion. The decrease
in LC number on treatment with IL-l ~ specific antibody also supports this possibility
(Fig. 4). Treatment with the 100 llg/mL antibody against IL-I a was without effect on the
influx of LC as depicted in Figure 5 while I00 ~lg/mL antibody against GM-CSF
produced ambiguous results. Interestingly again anti-IL-la seemed to have caused som
depletion on its own. A peculiar aspect of this experimental set up was that the controls
were much below the range (800-1000/mm\ This could loosely be attributed to the
possible LPS contamination of the media, as in previous case, or to the age of mice used
in these series of experiments. Some researchers in the past have established a direct
relationship between the number of LCs residing ill the skin and the age of the organism.
In Figure 6, it is illustrated that antibody against GM-CSF on its own caused some
depletion in LC number.
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Figure 3. III vitro blocking of Anti-CD80 induced LC depletion by Anti-T F Antibodies.
Pretreatments of mice with antibodies are same as described in the legend to Fig. I. The
results are expressed as mean +/- of the SEM from three independent experiments (i.e .. 3
mice per treatment group). Statistically significant difference in the means of the control
group and the other groups treated with various antibodies are indicated by an *.
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Figure 4. In vitro blocking of Anti-CD80 induced LC depletion with Anti-Ill beta.
Pretreatments of mice with antibodies are same as described in the legend to Fig. I. The
results were generated from two experiments as the mean +/- of the SEM. Statistically
significant difference in the means of the control group and the other groups treated with
various antibodies are indicated by an *.
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Figure 5. In vitro blocking of Anti-CD80 induced LC depletion with Anti-ILl alpha
antibody. Pretreatments of mice with antibodies are same as described in the legend to
Fig. 1. The results were obtained as mean +/- of the SEM from two independent
experiments. Statistically significant difference in the means of the control group and the
other groups treated with various antibodies are indicated by an •.
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To explain this the LPS induced depletion theory could be revoked but few other
possibilities are discussed with in the chapter IV. When administered concomitantly with
anti-CD80 antibody it blocked the effect of anti-CD80 antibody induced LC depletion but
to a lesser extent. The Student's t-test and Dunnett's t-test showed a statistically
insignificant outcome for the anti-IL-la and the anti-GM-CSF-induced effects.
Overall, these results implicate TNFa as a primary mediator of anti-CD80 induced
depletion and GM-CSF as a secondary mediator due to its less pronounced effect.
Cytokioe Secretion by Epidermal Cells
One of the important questions to be addressed was whether cytokines play an
upstream or a downstream role in anti-CD80 induced depletion effect. Earlier studies
demonstrated cytokine production by epidermal cell populations. Hence, immunoassays
were performed to analyze the secretion of TNFa and GM-CSF by epidermal c lis on
treatment with anti-CD80 antibody. Whole epidermal cell suspensions at a concentration
of 1 x 106 cells/mL were cultured for 24 hours at 37°C in the presence TNFa, IL-l P.
GM-CSF separately and in combination with anti-CD80 antibody to determine the levels
of TNFa secreted using Quantikine™ murine TNF immunoassay kit (data not shown).
The data obtained from two such experiments does not demonstrate that TNFa
expression was induced exclusively as a result of anti-C080 treatment to any significant
level. On the contrary, control and the groups treated with IL-I. GM-CSF individually
and in combination with anti-CD80 also showed comparable levels ofT Fa production
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Figure 6. In vitro blocking of Anti-CD80 induced depletion by Anti-GM-CSF
Antibodies. Pretreatments of mice with antibodies are same as described in the legend to
Fig. 1. The results are expressed as the mean +/- of the SEM obtained from two
experiments. Statistically significant difference in the means of the control group and the
other groups treated with various antibodies are indicated by an *.
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which were in the range of 200 pglmL. The experiment was repeated ith 48 hours time
point with out any significant change in the level of expJ1ession of 1: 0.. In addition to
TNFo., whole epidermal suspensions were exposed to the same set of cytokines for 48
hours and assayed for GM-CSF production in three separate experiments using
Quantikine™ murine GM-CSF kit. The results again indicated that there was negligibl
difference in the levels of GM-CSF induced as a result of anti-CD80 treatment wh n
compared with either control group or other treatments. The GM-CSF concentration was
approximately in the range of 220 to 250 pglmL in all cases except when the treatment
involved exposure to GM-CSF itself in which 'case it was 500 pglmL, presumably due to
the presence of residual cytokine. The results of this study show that the cytokine
production by anti-CD80 may not possibly explain the anti-CD80 effect. Thus, it is more
likely that cytokine upregulation of CD80 expression; GM-CSF (116) and TNFo. in
particular, may explain anti-CD80 induced mobilization of LC as depicted in the Figure
6. The data presented in the Table 1 indicate that modulation ofCD80 expression by GM-
CSF and TNF was not very substantial. But considering that LCs compris -1 % of total
EC population, and only a subset of these LCs might express CD80, the results seem
interesting. Also of some import is the fact that trypinization of epidennis to obtain cell
suspension (indirect immunofluoresence staining) impairs the expression of CD80 (63b).
To avoid this in the future, enzymes such as dispase can be used as a substitute.
Summary
The outcome of the various experiments undertaken in this study has revealed important
information about the aspect of LC migration via the engagement of the costimulatory
molecule CD80 that is expressed on its surface during maturation. The results sindicate
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significant involvement of cytokine TNFa in anti-CD80 induced migration of LC from
epidennis. It also showed that cytokine GM-CSF, adhesion molecules ICAM-l and to
lesser extent LFA-I may possibly be involved in the anti-CD80 induced migration
process while ruling out the involvement of IL-I. ELISAs for GM-CSF and TNFa did
not detect significant differences in the levels of these cytokines secreted among various
groups. These results support the possibilities that cytokine induction is probably not the
cause of the anti-CD80 induced effect. The mechanism by which anti-CD80 antibody
causes depletion is unknown, though the possibility that these cytokines might exert an
affect pror to anti-CD80 induced migratory pathway cannot be ruled out completely.
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Table I
Percentage of CD80-positive epidennal cells as obtained by Indirect
Immunofluorescence Staining. The epidennal cells were cultured
with TNF and GM-CSF for 24 hours, stained with FITC-CD80
Abs and observed under fluorescence microscope
Treatments TNFa +
Percentage of Control TNFa GM-CSF GM-CSF
FITC positive
cells =>
Trial 1 0.7<) 3.25 2.5 2.88
Trial 2 0.83 2.1 1.8 3.3
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CHAPTER IV
DISCUSSION
r.
There is no doubt that the induction of LC migration is one of the important
physiological events occurring in the skin with an imminent effect on the activation stat
of naive and quiescent T-cells and hence by extension on all T cell dependent cutaneous
immune responses (84). Antigen loaded LCs move down the afferent lymphatic vessels
to T-cell ricb paracortical regions of the lymph node where they encounter and activate
T-cells. The activated T cells then enter or "home" towards the original site of
inflammation and bring about a secondary phase of the immune response (152). An
impressive quantity of data regarding the factors eliciting LC departure from epidermis
has accumulated over last few years. T~e complete understanding of the molecular
mechanisms involved in the migration process is still being unraveled. Hence, th
knowledge gained so far is mostly fragmentary, and some results are seemingly
inconsistent and conflicting. It is of utmost importance to obtain an overall picture to
exploit the potential of LCs and by extension DCs, in immunotherapy.
As reported earlier, diverse factors such as antigens, chemical aHergens, UV light,
FITC, cytokines and several members of chemokine family induce the vectorial
movement of LCs (40, 9, 77, 95, 76, 236). The morphological changes influence the
functional aspects of LC and involve upregulation of CD80, CD86, CD40, CD54 and
MHC IT molecules (5). It is imperative to stress that maturation and migration processes
occur paraHel to each other. Hence, the questions arises whether molecules such as
CD80 that are traditionally associated with the maturation process of LC and the
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costimulation of virgin and resting T cells, are also involved in the migration of LCs.
Though traditionally CD80 and CD86 were associated with regulation ofT c 11 activation
versus tolerance, we have hypothesized that CD80 may influenoe LC egress and
localization by triggering signaling pathways on ligation with CD28/CTLA-4 in ivo.
Thus the crosslinking of the ligand pairs may operate in reciprocal dir ctions. We
assumed for our present study that crosslinking of CD80 with its antibody mimics th
engagement of CD80 receptor with its ligand CD28 or CTLA-4 on T cells.
In the present endeavor, we have attempted to uncover an unknown facet of CD80.
In the course of this, we have investigated and analyzed a triad of questions. Do
antibodies against CD80 induce a change in the frequency of LC number in the murine
epidermis? If yes then, is the change in the frequency due to migration? If yes again, then
do the cytokines influence the anti-CD80 induced migration?
As reported earlier, adhesion molecules and their ligands actively participate in
cutaneous inflammatory episodes by directing leukocyte trafficking and by mediating
antigen presentation. Modifications in adhesion molecule expression were reflected by
changes in the cell morphology including cell depolarization, the appearance of filopods
and loss of adherence (13). Anti-ICAM-l and anti-LFA-l antibodies have been shown to
prevent allo-graft rejections and contact hypersensitivity among others. In particular,
ICAM-I specific antibody has been observed to have had a pronounced effect on contact
sensitivity induced LC migration while LFA-I effected LC migration to a lesser degree
(129). Our fmdings that i.p. administration of antibodies against CD80 causes depletion
in LC density can be supported by the fact that anti-ICAM-] antibody and to a certain
extent anti- LFA-l antibody block the anti-CD80 induced effect. This also allows us to
speculate that the depletion may be due to migration of the LC from epidermis.
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Therefore, our data agree with the above obseIVations to a certain extent. Ho er th
synergistic effect of anti-ICAM-I and anti-LFA-I reported by Ma et al. was not se n in
our case (129). Our results indicate that both these adhesion molecules must b use a
similar mechanism in the induction of migration. The lower effect of anti-LFA-I might
be attributed to a lower level expression of LFA-I by immunocompetent cell in tb
epidermis or to the amounts of antibody used as well as the fact that LFA-I can coupl
with its ligand ICAM-I only upon activation. In fact, Ma and others barely detected the
presence of LFA-Ion LCs by immunohistochemical techniques and also observed that
endothelial cells do not express LFA-I (129). Activation ofLFA-l on T cells was shown
to have occurred via engagement of different cell surface receptors. For instance antibody
and CD28 crosslinking (187) and, TCR and MHC 11 interactions were observed to have
had an influence upon the LFA-l and ICAM-l interactions (221). Therefore, one
possible explanation for blockade of anti-CD80 induced LC migration by anti- ICAM-l
and anti-LFA-l is that crosslinking of antibody with C080 initiates LFA-l and ICAM-I
interaction by producing some unknown signal.
OUf next goal was to examine the effect of cytokines that were reported in the
literature to have had an effect on LC migration- GM-CSF (89, 168), IL-la. (185), IL-lP,
TNFa. (41) on anti-C080 induced effect. Consequently, we examined the effect of anti-
cytokine antibodies on anti-C080 induced LC migration. We found that both anti-TNFa
and anti-GM-CSF though the latter to a lesser extent, seemed to have prevented the anti-
C080 induced effect on LC migration. While IL-la. and IL-I p were shown to have had a
negligible effect.
Two possibilities that might explain the influence of TNFa and GM-CSF are that
the antibody/CD80 crosslinking induces expresslOn of these cytokines and hence the
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effect, or that the cytokines were produced upstream of the anti-CD80 induced effect as
result of the trauma to tissue which was caused while recovering skin explants. B
performing TNFa. and GM-CSF ELISAs we tested these possibilities. Both the cytokines
were found to be secreted by all the treatment groups in fairly high amounts and no
significant difference was established between the control groups and the various groups
treated with CD80 specific antibodies. Hence one possible explanation might be that the
cytokines TNFa. and GM-CSF induce expression of CD80 molecules on LCs in vitro
culture since their expression on freshly isolated epidermal LCs was very poor (92, 34).
Recent evidence also indicates that a dramatic increase in the expression of CD80
occurred on acute myeloid leukemia cells on addition of GM-CSF and other cytokines.
Hence, our model contends that the upregulation of CD80 by itself does not cause egress
of LC from epidermis but once CD80 binds with antibodies, signals are generated in the
fonn of cytokines (Fig. 7) or chemokines that are eventually responsible for migration of
LC.
Some recent works in the literature indicate that ll..,-1 p or TNFa. is not sufficient to
induce CD80 expression on LCs in vivo (149) while others like Salgado showed that
TNFa. is required for upregulation of CD80 in vitro (170). It was also reported by Ozawa
et at. that while none of the antibodies to lL-l p, TNFa., or GM-CSF changed the
upregulation of Ia antigen, ICAM-l, or CD40 on cultured Langerhans cells, anti-GM-
CSF suppressed that of CD80 and CD86. Regardless, taken together the studies indicate
that IL-l p is required for the upregulation of la, ICAM-1, CD86, and CD40 and not for
the upregulation of CD80, while GM-CSF and TNFa. are required for the upregulation of
CD80 (34,170,149,150).
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Our results that anti-TNFa and anti-GM-CSF antibodies induced blockade of anti-
CD80 induced LC depletion can be explained based on the above-publish d works and
by evoking the overly-simplistic paradigm we put forward. The findings of Larsen et al.
also corroborate these observations and link GM-CSF induced upregulation of CD80
with functional maturation and migration of LCs out of skin (116, 177). Our data was
found to be statistically significant for anti-TNFa treatment and not for anti-GM-CSF.
This inconsistency can be attributed to the observation that GM-CSF apart from its effect
on migration also plays a role in LC precursor recruitment from circulating blood to the
skin (89). This also explains the partial decrease in LC number on administration of anti-
GM-CSF alone.
Alternatively, the effect of TNFa on LC migration can be attributed to its influence
on the regulation of the expression of adhesion molecules on LC (96). TNFa induced
endothelial E-selectin, intercellular adhesion molecule-l (lCAM-l) and vascular cell
adhesion molecule-l (V-CAM-1) in all groups, and adhesion molecule ICAM -1 and V-
CAM-l expression by interstitial dermal dendritic cells and ICAM-l by keratinocytes
was observed (74). Interwoven with this is one possiblity that crosslinking of C080 and
its antibodies effectively signals upregul.ation of ICAM-l and LFA-l indirectly and hence
the explanation that they mediate anti-C080 induced migration becomes much more
plausible. Another explanation might be that the antibody against C080 induces
chemokine production that directs mobilization of LCs from epidermis. Richins eL at
have shown that antibody against the chemokine MCP-l prevented depletion induced by
anti-CD86 (Richins unpublished).
The exact roles played by cytokines TNFa and GM-CSF or by the adhesion
molecules ICAM-I and LFA-I in anti-CD80 orchestrated LC migration have still to be
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elucidated. Also of the interest is the nature of the signals that regulate expression of the
adhesion molecules. Nevertheless, it may be that cytokines like TNFa or chemokines like
MCP-l serve as important mediators of anti-CD80 induced migration.
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Figure 7. Schematic representation of the mechanism involved in Langerhans cell
migration from murine epidermis on treatment with antibodies against CD80 co-
stimulatory molecule.
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